Kiniksa Pharmaceuticals International Balance Sheet
NASDAQ: KNSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kiniksa Pharmaceuticals International financial position
At the end of fiscal 2025, Kiniksa Pharmaceuticals International reported total assets of $763.6 million, up 31.5% from a year earlier against total liabilities of $196.0 million. Shareholders' equity stood at $567.6 million, or 74.3% of assets. The company held $165.6 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 3.79, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Kiniksa Pharmaceuticals International balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 165.60M | 183.58M | 107.95M | 122.72M | 122.47M | 114.04M | 46.93M | 71.98M | 45.55M |
| Short-Term Investments | 248.48M | 60.05M | 98.42M | 67.89M | 59.73M | 209.44M | 186.45M | 235.33M | 0 |
| Receivables | 15.59M | 41.72M | 21.27M | 12.66M | 3.98M | — | — | — | — |
| Inventory | 54.90M | 26.36M | 31.12M | 21.60M | 3.67M | 0 | — | — | — |
| Total Current Assets | 527.18M | 331.80M | 276.30M | 243.06M | 196.45M | 333.25M | 241.63M | 313.75M | 47.10M |
| Property, Plant & Equipment | 1.94M | 662.00K | 734.00K | 1.66M | 2.83M | 4.05M | 6.40M | 6.36M | 125.00K |
| Intangible Assets | 15.25M | 16.25M | 17.25M | 18.25M | 19.25M | 0 | — | — | — |
| Total Assets | 763.63M | 580.55M | 526.32M | 459.67M | 232.80M | 349.46M | 254.53M | 321.96M | 47.49M |
| Accounts Payable | 2.03M | 2.04M | 8.25M | 7.90M | 1.87M | 503.00K | 5.69M | 10.92M | 1.22M |
| Total Current Liabilities | 139.18M | 100.62M | 63.67M | 47.07M | 44.82M | 31.85M | 27.83M | 42.55M | 17.43M |
| Total Liabilities | 196.03M | 142.12M | 87.48M | 63.52M | 47.76M | 37.53M | 29.11M | 42.70M | 17.43M |
| Shareholders' Equity | 567.61M | 438.44M | 438.84M | 396.15M | 185.04M | 311.94M | 225.42M | 279.27M | -89.71M |
| Retained Earnings | -462.14M | -521.14M | -477.95M | -492.03M | -675.40M | -517.47M | -356.09M | -194.22M | -91.00M |
| Net Cash (Debt) | 414.07M | 243.63M | 206.37M | 190.61M | 182.20M | 323.48M | 233.38M | 307.30M | 45.55M |
This table shows 9 annual periods of Kiniksa Pharmaceuticals International's balance sheet, from FY 2025 back to FY 2017, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow KNSA's reporting calendar. What is a balance sheet?